Form 8-K BIOGEN INC. For: Jul 07

Go back to Form 8-K BIOGEN INC. For: Jul 07

Biogen (BIIB) Updates Q2 Guidance

July 7, 2025 4:12 PM EDT

Biogen (NASDAQ: BIIB) expects that its GAAP and non-GAAP results for the second quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $46 million on a pre-tax basis. The estimated charge is expected to impact GAAP and... More